The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice.
The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice.
复制标题
DOI：
10.3899/jrheum.080375
复制
发表时间：
2008-12
期刊：
影响因子：
--
通讯作者：
Hays RD
中科院分区：
文献类型：
--
作者：
Khanna D;Pope JE;Khanna PP;Maloney M;Samedi N;Norrie D;Ouimet G;Hays RD
疲劳是类风湿关节炎的常见症状，并在类风湿关节炎临床试验中用作结局指标。我们研究了一项大型学术临床实践，以使用患者报告的锚点（疲劳、疼痛和整体健康状况）估计疲劳视觉模拟量表的最小重要差异（MID）。RA患者（N=307）在2个时间点进行了门诊访视，中位时间间隔为5.9个月。他们完成了疲劳视觉模拟量表（VAS; 0-10）和回顾性锚项目，“您如何描述自上次访视以来您的总体疲劳/疼痛/总体健康状况？”更糟，更糟，更糟。疲劳锚用于主要分析，疼痛/整体健康锚用于敏感性分析。最小变化组定义为报告他们有所改善或有所恶化的患者。平均（SD）年龄为59.4（13.2）岁，病程为14.1（11.5）年，83%的患者为女性。基线平均（SD）HAQ-DI评分为0.84（0.75）。基线疲劳VAS评分为4.2（2.9），随访时为4.3（2.8）（平均变化为-0.07 [2.5]，p=NS）。对于疲劳锚，疲劳变化评分（0-10量表）稍好和稍差的平均值分别为-1.12和1.26。使用疼痛锚，疲劳变化评分略有改善和略有恶化的平均值分别为-0.87和1.13，使用全局锚，疲劳变化评分略有改善和略有恶化的平均值分别为-0.82和1.17。使用3个锚点的效应量（ES）估计值对于稍好（范围：0.27 - 0.39）和稍差（范围：0.40 - 0.44）组较小，但大于无变化组（范围：0.03 - 0.08）。在大型RA临床实践中，0-10量表上疲劳VAS改善的MID介于-0.82至-1.12之间，恶化的MID介于1.13至1.26之间，与RA临床试验中观察到的结果相似。该信息有助于解释临床实践中日常护理中的疲劳VAS。
Fatigue is a common symptom in RA and used as an outcome measure in RA clinical trials. We studied a large academic clinical practice to estimate the minimally important difference (MID) for a fatigue visual analog scale using patient-reported anchors (fatigue, pain and overall health). RA patients (N=307) had clinic visits at 2 time points at a median of 5.9 months apart. They completed fatigue visual analog scale (VAS; 0–10) and retrospective anchor items, “How would you describe your overall fatigue/pain/overall health since the last visit?” Much worsened, Somewhat worsened, Same, Somewhat better, or Much better. The fatigue anchor was used for primary analysis and the pain/ overall health anchors for sensitivity analyses. The minimally changed group was defined by those reporting they were somewhat better or somewhat worsened. The mean (SD) age was 59.4 (13.2) years, disease duration was 14.1 (11.5) years, and 83% of patients were women. The baseline mean (SD) HAQ-DI score was 0.84 (0.75). The baseline fatigue VAS score was 4.2 (2.9) and at follow up was 4.3 (2.8) (mean change of −0.07 [2.5], p=NS). The fatigue change score (0–10 scale) for somewhat better and somewhat worsened for fatigue anchor averaged −1.12 and 1.26, respectively. Using pain anchor, the fatigue changed score for somewhat better and somewhat worsened averaged −0.87 and 1.13 and using global anchor, the fatigue changed score for somewhat better and somewhat worsened averaged −0.82 and 1.17, respectively. Effect size (ES) estimates using 3 anchors were small for somewhat better (range: 0.27 to 0.39) and somewhat worsened (range: 0.40 to 0.44) groups but larger than the no-change group (range: 0.03 to 0.08). The MID for fatigue VAS is between −0.82 to −1.12 for improvement and 1.13 to 1.26 for worsening on 0–10 scale in a large RA clinical practice and similar to that seen in RA clinical trials. This information can aid in interpreting fatigue VAS in day-to-day care in clinical practice.
登录
查看更多内容
影响因子：
27.4
作者：
Kvien, TK;Mowinckel, P;Uhlig, T
通讯作者：
Uhlig, T
DOI：
10.1016/0197-2456(89)90005-6
发表时间：
1989-12-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
JAESCHKE, R;SINGER, J;GUYATT, GH
通讯作者：
GUYATT, GH
影响因子：
--
作者：
Krishnan, E;Sokka, T;Hannonen, P
通讯作者：
Hannonen, P
影响因子：
4.5
作者：
Yost, KJ;Sorensen, MV;Cella, D
通讯作者：
Cella, D
影响因子：
3.5
作者：
Ferguson, RJ;Robinson, AB;Splaine, M
通讯作者：
Splaine, M